

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office: 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA) Corporate Office: Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083 Phone: 91-11 - 69041000 Fax: 91-11 27023256 E-mail: akumsho@akums.net; website: www.akums.in

September 12, 2024

Ref: Akums/Exchange/2024-25/15

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E),Mumbai – 400 051

To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze
Jeejeebhoy Towers, Dalal
Street, Fort, Mumbai - 400 001

Symbol: AKUMS Scrip Code: 544222

Sub: Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Grant of Patent Certificate

Respected Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that The Patent Office, Government of India, has granted Patent Certificate (enclosed) to the Company today i.e. September 12, 2024 for its invention titled "ROOM STABLE HYDROXYUREA ORAL SUSPENSION" valid for a term of 20 years in accordance with the provisions of the Patents Act, 1970.

The Patent "Room Stable Hydroxyurea Oral Suspension" is a breakthrough formulation aimed at managing Sickle Cell Disease (SCD). This development reinforces company's role as an innovator in pharmaceutical solutions, offering a significant advance in addressing the storage and accessibility challenges associated with Hydroxyurea solution.



ISO 9001 : 2015 ISO 14001 : 2015 ISO 17025 : 2005 (NABL) WHO-GMP US: NSF HACCP







AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office: 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA) Corporate Office: Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083 Phone: 91-11 - 69041000 Fax: 91-11 27023256 E-mail: akumsho@akums.net; website: www.akums.in

Sickle Cell Disease, a genetic blood disorder, leads to severe health complications such as anemia, frequent pain episodes and other debilitating symptoms, affecting millions worldwide especially in India and Africa. According to the 2011 Census, 8.6% of India's population is from tribal communities, many of whom are disproportionately affected by SCD. Addressing this pressing public health issue, company's new formulation offers a key advantage over traditional Hydroxyurea solution that require refrigeration between 2–8°C. The new oral suspension remains stable at room temperature, providing a practical solution for widespread distribution, particularly in the tribal areas with limited access to cold storage facilities.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik Company Secretary & Compliance Officer

Encl: As above



ISO 9001 : 2015 ISO 14001 : 2015 ISO 17025 : 2005 (NABL) WHO-GMP US: NSF HACCP











्र भाग पेटेंट प्रमाण पत्र Patent Certificate

पेटंट कायोलय, भारत सरकार The Patent Office, Government Of India

(पेटेंट नियमावली का नियम 74) (Rule 74 of The Patents Rules)

सरकार **पेटेंट** सं.7 Patent No. मठवरत. ७५०७७ ७२८७१ ७७४७ ७ , ५५७१२७ ७, ००७०७० ८ ७०७०७०, बीद्धिक संपदा वा कार्यालय. भारत सरकार छी।

आवेदन सं. / Application No. वि नार्यालय, भारत शरकार 202311063613 من منافق الليكيون برايري कावेदन सं. / Application No.

खुन्छ ५**२०/०९/२०२३** संपदा दपतर. भारत सरकार, खाँफ्रिक जल्लान कार्यालय खाँ

Akums Drugs & Pharmaceuticals limited

్యాకం కాయ్ కోస్కు స్థించున్ని మేదో సంపతి కార్యాలయము, భారత ప్రభుత్వవడు, శాహెక్ రహి

लेक्प्रकेल के जिल्लाह एएक पॉल कपार्वा है। जो जीने जना जिल्लाम अपने सरकार बोद्धिक संपदा क

حد ,அற்திய அரசு ف دي الشليكحواليرا

प्रमाणित किया जाता है कि पेटेंटी को, उपरोक्त आवेदन में यथाप्रकटित ROOM STABLE HYDROXYUREA ORAL SUSPENSION नामक आविष्कार के लिए, पेटेंट अधिनियम, 1970 के उपबंधों के अनुसार आज तारीख सितम्बर 2023 के बीसवें दिन से बीस वर्ष की अवधि के लिए पेटेंट अनुदत्त किया गया है।

It is hereby certified that a patent has been granted to the patentee for an invention entitled ROOM STABLE HYDROXYUREA ORAL SUSPENSION as disclosed in the above mentioned application for the term of 20 years from the 20th day of September 2023 in accordance with the provisions of the Patents Act.1970.

> ය සමහල් ගරුවන්? මුවලින්ව වන්වන් වු වන්වෙන්වන්. වැඩින්වෙන්ට වන්වෙන්, මोद्धिक संपदा पा प्राप्तित्य आहर्त ு வரிவுகர் மிற்றவல்கம். இந்திய அரசு به வரிவுசார் சொந்து அலுவலகம். இந்திய அரசு به دو الشكر في الشكر في المستحرفين الم बोदिक सम्पन्ति कार्यालये भारत सरकार. عن حكومت بند अधिक सम्पन्ति कीर्यालये अधिक राज्यकेका कार्य

नवां विसंधान , भारत सरकार, बौद्धिक संघटा कार्यालय প্রাথার : 12/09/2024 Date of Grant : : 12/09/2024

Controller of Patents

انقىلىكچولىرايرئىگورنمنىڭ آف

टिप्पणी - इस पेटेंट के नवीकरण के लिए फीस, यदि इसे बनाए रखा जाना है, सितम्बर 2025 के बीसवें दिन को और उसके पश्चात प्रत्येक वर्ष में उसी दिन देय होगी। Note. - The fees for renewal of this patent, if it is to be maintained, will fall / has fallen due on 20th day of September 2025 and on the same day in every year thereafter.

چو .அரத்திய அரசு . و انتشار அரத்து அலுவலகம். இந்திய அரசு . فقس آف دی انتشار شور الرائدگورسیت آف انتشا

కార్యాలయము. భారత పడుత్వము. ४°विशा अमारो**व वि**विद्या है है गिराम "एउ प्रोप्त है कि प्राप्त निर्मान स्वा विस्थान , भारत सरकार, बीद्धिक सपर